净利增速降至个位数，隐形眼镜能否撑起爱博医疗新增长？

Core Insights - Aibo Medical reported a revenue of 787 million yuan for the first half of 2025, marking a year-on-year growth of 14.72%, although the growth rate has slowed compared to previous years [1][3] - The net profit attributable to shareholders was 213 million yuan, reflecting a modest increase of 2.53%, significantly lower than the double-digit growth seen in prior years [1][3] - The company's core revenue from artificial lenses has been declining, while the contact lens business has shown rapid growth, potentially becoming a new growth driver [1][4] Financial Performance - Revenue for the first half of 2025 was 787 million yuan, up from 686 million yuan in the same period last year, representing a growth of 14.72% [2] - Net profit attributable to shareholders was 213 million yuan, compared to 208 million yuan in the previous year, with a growth rate of 2.53% [2] - The net profit after deducting non-recurring gains was 204 million yuan, showing a year-on-year increase of 2.63% [2] Product Performance - Revenue from artificial lenses was 345 million yuan, with a year-on-year growth of 8.23%, but its revenue share decreased from 46.49% in mid-2024 to 43.86% [4] - The contact lens business generated 236 million yuan in revenue, a significant increase of 28.89%, and its share of total revenue rose to 30.06% [4][6] - The overall decline in net profit growth is attributed to lower profit margins on certain products and an increase in the share of lower-margin products like contact lenses [4] Strategic Moves - Aibo Medical has strategically entered the contact lens market through acquisitions, including a 55% stake in Tianyan Pharmaceutical and a 51% stake in Fujian Younikang [6][7] - The company plans to raise up to 300 million yuan to expand its contact lens production capacity, aiming for an annual output of 252 million lenses [7] - Despite the growth in the contact lens segment, the lower profit margins present challenges, with the contact lens business having a gross margin of 26.18%, significantly lower than that of artificial lenses at 89.16% [7][8] Market Outlook - Analysts suggest that while the contact lens business is growing rapidly, it has not yet compensated for the decline in the artificial lens segment [8] - Aibo Medical needs to enhance the gross margin of its contact lens products and optimize its product structure in the artificial lens segment to address market challenges [8]